Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 304Carcinoma, Non-Small-Cell Lung 182Ovarian Neoplasms 154Lung Neoplasms 92Esophageal Neoplasms 75Triple Negative Breast Neoplasms 71Stomach Neoplasms 71Fallopian Tube Neoplasms 68Squamous Cell Carcinoma of Head and Neck 51Esophageal Squamous Cell Carcinoma 50Neoplasm Metastasis 48Neoplasms 45Endometrial Neoplasms 42Head and Neck Neoplasms 41Carcinoma, Ovarian Epithelial 41Uterine Cervical Neoplasms 37Recurrence 26Carcinoma, Squamous Cell 23Adenocarcinoma Of Esophagus 22Urinary Bladder Neoplasms 19Melanoma 19Inflammatory Breast Neoplasms 19Prostatic Neoplasms 18Adenocarcinoma of Lung 17Carcinoma 15Breast Neoplasms, Male 15Unspecified Adult Solid Tumor, Protocol Specific 14Testicular Neoplasms 13Small Cell Lung Carcinoma 12Peritoneal Neoplasms 12

Interventions

Fulvestrant 6olaparib 4Letrozole 4trastuzumab deruxtecan 3Aromatase Inhibitors 3Anastrozole 3sacituzumab govitecan 2pyrotinib 2eribulin 2dalpiciclib 2Paclitaxel 2Goserelin 2Gonadotropin-Releasing Hormone 2FCN-437c 2Capecitabine 2toripalimab 1talazoparib 1sonidegib 1ribociclib 1pembrolizumab 1neratinib 1liposomal doxorubicin 1elacestrant 1disitamab vedotin 1ceralasertib 1capivasertib 1balixafortide 1apatinib 1abemaciclib 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Advanced Breast Cancer × Paclitaxel × Clear all
NCT07602907 2026-05-22

Metronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
44 enrolled
Breast

Advanced Breast Cancer

NCT02599363 2023-11-09

A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
18 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡